Early Phase Study of Kesonotide in Participants With Solid Tumours
Status:
NOT_YET_RECRUITING
Trial end date:
2027-10-26
Target enrollment:
Participant gender:
Summary
This clinical trial is an adaptive study of a novel vimentin inhibitor in cancers.
It is an open label, multicentre, single ascending dose level in phase I and cohort exploration in phase II.
Primary objective is to evaluate safety and tolerability of kesonotide as a monotherapy in participants with advanced/metastatic solid cancers.
Secondary objective is to characterise the pharmacokinetics of kesonotide. Phase I study will enrol 20-32 participants and Phase II approximately 80 participants.